The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: Empirical findings and public policy implications

International Journal of Research in Marketing

Volumn 28, Issue 3, 2011, Pages 205-217

  Liu, Qiang ^a   Gupta, Sachin ^b  

^a PURDUE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Advertising; DTCA; Econometrics; Health care; Pharmaceuticals

Indexed keywords

EID: 80052561913     PISSN: 01678116     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijresmar.2011.04.001     Document Type: Article

References (57)

1. AHRQ Household component of the medical expenditure panel survey 2005, Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality.
2. Altman D., Cutler D.M., Zeckhauser R.J. Adverse selection and adverse retention. The American Economic Review 1998, 2:122-126.
3. Avery R., Kenkel D., Lillard D.R., Mathios A., Wang H. Health disparities and direct-to-consumer advertising of pharmaceutical products. Advances in Health Economics and Health Services Research 2008, Vol. 19:71-94. Emerald Group Publishing Limited.
4. Azoulay P. Do pharmaceutical sales respond to scientific evidence?. Journal of Economic Management Strategy 2002, (4):551-594.
5. Bayer Corporation Americans with elevated cholesterol under-treated 2001, May 17, http://www.pslgroup.com/dg/1FB6F6.htm.
6. Berndt E.R., Bui L., Reiley D.R., Urban G.L. Information, marketing, and pricing in the US antiulcer drug market. The American Economic Review 1995, 100-105.
7. Calfee J.E., Winston C., Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. Jornal of Law and Economics 2002, 672-690.
8. Centers for Disease Control and Prevention Progress in chronic disease prevention factors related to cholesterol screening and cholesterol level awareness-United States, 1989. Morbidity and Mortality Weekly Report 1990, September 21.
9. Christen M., Gupta S., Porter J., Staelin R., Wittink D.R. Using market-level data to understand promotional effects in a non-linear model. Journal of Marketing Research 1997, 322-334.
10. Dalzell M.D. Direct-to-consumer advertising: Can everyone's interests be balanced?. Managed Care 1999, (12). 28-32,35.
11. Evans C., Tavakoli M., Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal. Health Care Management Science 2004, 43-49.
12. Findlay S.D. Direct-to-consumer promotion of prescription drugs. economic implications for patients, payers, and providers. PharmacoEconomics 2001, 109-119.
13. Ford I., Murray H., Packard C., Shepherd J., Macfarlane P.W., Cobbe S.M. Long-term follow-up of the west of Scotland coronary prevention study. The New England Journal of Medicine 2007, 1477-1486.
14. Fryar C.D., Hirsch R., Eberhardt M.S., Yoon S.S., Wright J.D. Hypertension, high serum total cholesterol, and diabetes: Racial and ethnic prevalence differences in US adults, 1999-2006. NCHS Data Brief No. 36 2010, April.
15. Gelman A., Carlin J.B., Stern H.S., Rubin D.B. Bayesian Data Analysis 1998, Chapman & Hall/CRC.
16. Gönül F.F., Carter F., Wind J. What kind of patients and physicians value direct-to-consumer advertising of prescription drugs. Health Care Management Science 2000, 215-226.
17. Hollon M.F. Direct-to-consumer marketing of prescription drugs: creating consumer demand. Journal of the American Medical Association 1999, 281:382-384.
18. Holmer A.F. Direct-to-consumer prescription drug advertising bridges between patients and physician. Journal of the American Medical Association 1999, 281:380-382.
19. Hueston W.J., Spencer E., Kuehn R. Differences in the frequency of cholesterol screening in patients with Medicaid compared with private insurance. Archives of Family Medicine 1995, 331-334.
20. Iizuka T., Jin G.Z. The effect of prescription drug advertising on doctor visits. Journal of Economic Management Strategy 2005, 701-727.
21. Iizuka T., Jin G.Z. Direct-to-consumer advertising and prescription choice. The Journal of Industrial Economics , Notes and Comments page 2007, Published at. http://www.essex.ac.uk/jindec/notes.htm.
22. IMS Health US physicians responsive to patient requests for brand-name drugs. New IMS Physician Perception Study Gauges Effect of Pharmaceutical Promotions on Prescribing Behavior of More than 2,300 U.S. Physicians 2002.
23. IMS Health Total US promotional spend by type 2007 2007, (About US, Press Room, 2007 Top-Line Industry Data, U.S.). http://www.imshealth.com/.
24. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in patients with hypercholesterolemia (the curves study). The American Journal of Cardiology 1998, 5:582-587.
25. Jones P., Davidson M., Stein E., Bays H., McKenney J., Miller E., et al. Comparison of the efficacy and safety of Rosuvastatin versus Atorvastatin, Simvastatin, and Pravastatin across doses (stellar trial). The American Journal of Cardiology 2003, 2:152-160.
26. Kleibergen F., Zivot E. Byesian and classical approaches to instrumental variable regression. Journal of Econometrics 2003, 29-72.
27. Klittich J.C.W., McGuire A., Ford I., Norrie J., Pettitt D., McMurray J., et al. The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with Pravastatin. British Medical Journal 1997, 1577-1582.
28. Kremer S.T.M., Bijmolt T.H.A., Leeflang P.S.H., Wieringa J.E. Generalizations on the effectiveness of pharmaceutical promotional expenditures. International Journal of Research in Marketing 2008, 234-246.
29. Kung H.C., Hoyert D.L., Xu J., Murphy S.L. Deaths: Final data for 2005. National Vital Statistics Reports 2008.
30. Larsen J., Andersen M., Kragstrup J., Gram L. High persistence of statin use in a Danish population: compliance study 1993-1998. British Journal of Clinical Pharmacology 1998, 375-378.
31. Lee D., Zhou L. An empirical test of SES and media use: Modeling the knowledge gap hypothesis in the TV versus newspaper context 2004, The annual meeting of the International Communication Association, New Orleans, LA. http://www.allacademic.com/meta/p112637_index.html.
32. Maddala G.S., Kim I. Unit Roots, Cointegration, and Structural Change 1998, Cambridge University Press.
33. Morrison A., Glassberg H. Determinants of the cost-effectiveness of statins. Journal of Managed Care Pharmacy 2003, 544-551.
34. Mullahy J. Instrumental-variable estimation of count data models: Applications to models of cigarette smoking behavior. The Review of Economics and Statistics 1997, 79(4):586-593.
35. Narayanan S., Manchanda P. Heterogeneous learning and the targeting of marketing communication for new products. Marketing Science 2009, 3:424-441.
36. Narayanan S., Desiraju R., Chintagunta P.K. Return on investment implications for pharmaceutical promotional expenditures: the role of marketing-mix interactions. Journal of Marketing 2004, 90-105.
37. Nerlove M., Arrow K.J. Optimal advertising policy under dynamic conditions. Economica 1962, 29:129-142.
38. Neumann P., Sandberg E., Bell C., Stone P., Chapman R. Are pharmaceuticals cost effective? A review of the evidence. Health Affairs 2000, 19:92-109.
39. Osinga E.C., Leeflang P.S.H., Srinivasan S., Wieringa J.E. Why do firms invest in consumer advertising with limited sales response? A shareholder perspective. Journal of Marketing 2011, 75(1):109-124.
40. Palda K.S. The measurement of cumulative advertising effects. Journal of Business 1965, 162-179.
41. Piani A., Schoenbom C. Health promotion and disease prevention: United states, 1990. Vital Health Statistical 1993, 1-88.
42. Prosser L.A., Stinnett A.A., Goldman P.A., Williams L.W., Hunink M.G.M., Goldman L., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Annals of Internal Medicine 2000, 769-779.
43. Robinson M., Dehaven M., Wallace B., Fost T. Hypercholesterolemia: case finding in family practice. Southern Medical Journal 1992, 1091-1095.
44. Robinson A., Hohmann K., Rifkin J., Gilroy C., Pickard J., Anderson R. Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Archives of Internal Medicine 2004, 4:427-432.
45. Rosenthal M.B., Berndt E.R., Donohue J.M., Epstein A.M., Frank R.G. Demand effects of recent changes in prescription drug promotion. Frontiers in Health Policy Research 2003, 1-26.
46. Sabaté E. Adherence to Long term Therapies: Evidence for Action 2003, World Health Organization, Geneva.
47. Shepherd J., Cobbe S., Ford I. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia. The New England Journal of Medicine 1995, 1301-1307.
48. Staiger D., Stock J.H. Instrumental variables regression with weak instruments. Econometrica 1997, 557-586.
49. Stange K.C. Time to ban direct-to-consumer prescription drug marketing. Annals of Family Medicine 2007, 2:101-104.
50. Steven R., Carper K. Expenses for office-based physician visits by specialty. Agency for Healthcare Research and Quality, Statistical Brief 166 2004.
51. Stremersch S. Health and marketing: The emergence of a new field of research. International Journal of Research in Marketing 2008, 229-233.
52. Stremersch S., Lemmens A. Sales growth of new pharamaceuticals across the globe: The role of regulatory regimes. Marketing Science 2009, 690-708.
53. Walsh J., Baron R., Browner W. Predictors of screening for hypercholesterolemia in a general internal medicine practice. The Western Journal of Medicine 1993, 58:359-363.
54. Wittink D.R. Exploring territorial differences in the relationship between marketing variables. Journal of Marketing Research 1977, 145-155.
55. Wosinska M. Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. HBS Marketing Research Paper Series, No. 02-04 2002.
56. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. Journal of Marketing Research 2005, 323-332.
57. Zhou Z., Rahme E., Pilote L. Are statins created equal? Evidence from randomized trials of Pravastatin, Simvastatin, and Atorvastatin for cardiovascular disease prevention. American Heart Journal 2006, (2):273-281.